1. Home
  2. TNET vs TSHA Comparison

TNET vs TSHA Comparison

Compare TNET & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TriNet Group Inc.

TNET

TriNet Group Inc.

HOLD

Current Price

$42.84

Market Cap

1.7B

ML Signal

HOLD

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

HOLD

Current Price

$5.43

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNET
TSHA
Founded
1988
2019
Country
United States
United States
Employees
2700
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.8B
IPO Year
2000
2020

Fundamental Metrics

Financial Performance
Metric
TNET
TSHA
Price
$42.84
$5.43
Analyst Decision
Hold
Strong Buy
Analyst Count
5
8
Target Price
$65.80
$11.63
AVG Volume (30 Days)
336.0K
2.2M
Earning Date
04-30-2026
05-06-2026
Dividend Yield
2.57%
N/A
EPS Growth
N/A
5.56
EPS
1.90
N/A
Revenue
$5,010,000,000.00
$9,773,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$3.30
$1,152.42
P/E Ratio
$21.30
N/A
Revenue Growth
N/A
17.28
52 Week Low
$33.67
$2.25
52 Week High
$86.78
$7.30

Technical Indicators

Market Signals
Indicator
TNET
TSHA
Relative Strength Index (RSI) 57.78 38.37
Support Level $34.47 $5.37
Resistance Level $46.38 $6.02
Average True Range (ATR) 2.28 0.43
MACD -0.19 -0.19
Stochastic Oscillator 59.76 2.85

Price Performance

Historical Comparison
TNET
TSHA

About TNET TriNet Group Inc.

Trinet Group Inc provides human resources solutions for small and medium-sized businesses through technology-enabled services. Its offerings include human capital expertise, employee benefits such as health insurance and retirement plans, payroll and payroll tax administration, risk mitigation, and compliance consulting. The company provides its services through professional employer organization (PEO) services delivered via a co-employment model, as well as administrative services organization (ASO) offerings. The majority of the company's revenue is derived from the insurance-related billings and administrative fees collected from PEO clients.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

Share on Social Networks: